4DMT Reports Third Quarter 2024 Financial Results ... - BioSpace

3 days ago · EMERYVILLE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic …

CouponFollow Extension

$31
OFF

4DMT Reports Second Quarter 2024 Financial Results And …

1 week from now

R&D Expenses: Research and development expenses were $31.9 million for the second quarter of 2024, as compared to $23.6 million for the second quarter of 2023. This increase was …

4dmoleculartherapeutics.com

1%
OFF

Scientific Industries Reports Third Quarter 2024 Financial Results

1 week from now

1 day ago · Third Quarter and Nine Months Financial Highlights: Net revenues totaled $2.8 million, an increase of 7.1%, and $7.9 million, a decrease of 5.7%, respectively, for the three- and nine …

biospace.com

$4
OFF

Plus Therapeutics Reports Third Quarter 2024 Financial ... - BioSpace

1 week from now

2 days ago · The Company’s cash and investments balance was $4.8 million at September 30, 2024 compared to $8.6 million at December 31, 2023. In addition, the Company received a …

biospace.com

FAQs about 4DMT Reports Third Quarter 2024 Financial Results ... - BioSpace Coupon?

What were Q2 2024 financial results?

Q2 2024 Financial Results Cash and Cash Equivalents and Marketable Securities: Cash and cash equivalents and marketable securities were $578 million as of June 30, 2024, as compared to $299 million as of December 31, 2023. ...

Is 4DMT a trademark of 4D Molecular Therapeutics?

In addition, 4DMT is also advancing programs in CNS through a gene editing partnership. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT. ...

What were G&A expenses in the second quarter of 2024?

G&A Expenses: General and administrative expenses were $10.6 million for the second quarter of 2024, as compared to $8.8 million for the second quarter of 2023. Net Loss: Net loss was $35.0 million for the second quarter of 2024, as compared to net loss of $29.6 million for the second quarter of 2023. About 4DMT ...

What are 4DMT's clinical-stage and preclinical product candidates?

Currently, 4DMT is advancing six clinical-stage and one preclinical product candidate, each tailored to address rare and large market diseases in ophthalmology, pulmonology and cardiology. ...